Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common stock, par value $0.001 per share (the "Common Stock")
-
Shares outstanding
-
139M
-
Number of holders
-
270
-
Total 13F shares, excl. options
-
71.8M
-
Shares change
-
-639K
-
Total reported value, excl. options
-
$2.56B
-
Value change
-
-$10.5M
-
Put/Call ratio
-
0.86
-
Number of buys
-
117
-
Number of sells
-
-132
-
Price
-
$35.66
Significant Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR) as of Q2 2023
310 filings reported holding ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") as of Q2 2023.
ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR) has 270 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.8M shares
of 139M outstanding shares and own 51.71% of the company stock.
Largest 10 shareholders include BlackRock Inc. (12.8M shares), VANGUARD GROUP INC (11M shares), STATE STREET CORP (5.51M shares), JPMORGAN CHASE & CO (2.88M shares), FMR LLC (2.72M shares), Invesco Ltd. (2.23M shares), GEODE CAPITAL MANAGEMENT, LLC (2.15M shares), Rokos Capital Management LLP (1.68M shares), CREDIT SUISSE AG/ (1.43M shares), and NORTHERN TRUST CORP (1.3M shares).
This table shows the top 270 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.